智通财经APP获悉，三生制药(01530)再涨超12%，年内股价已实现翻倍。截至发稿，涨12.75%，报12.2港元，成交额4.87亿港元。
消息面上，3月25日，三生制药发布截至2024年12月31日止年度业绩，该集团期内取得收入91.08亿元人民币，同比增加16.5%；母公司拥有人应占纯利20.90亿元，同比增加34.9%；每股基本盈利0.86元；拟派发末期股息每股25港仙。公告称，收入增加主要由于特比澳、蔓迪及赛普汀的销售额强势增长。
展望2025年，集团将积极筹备柏瑞素（紫杉醇口服溶液）、特艾升（艾曲波帕混悬剂）、丽美治（盐酸那呋拉啡口崩片）等自研或合作创新药的市场准备工作。随着临床研究和申报流程的推进，公司预计2025年起集团将每年有重点新药进入商业化阶段。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.